Mednet Logo
HomeQuestion

In the treatment of lupus nephritis, which patients may benefit from the use of rituximab or other B-cell depleting agents during induction?

2
2 Answers
Mednet Member
Mednet Member
Rheumatology · Hackensack University Medical Center

I agree with @Dr. @Dr. First Last's previous answer (posted July 2020). In addition, the 2024 ACR Lupus Nephritis guidelines (discussed at the 2024 ACR meeting) still recommend mycophenolate (MMF) or cyclophosphamide as first-line induction therapies for lupus nephritis (LN), rather than B-cell depl...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Rheumatology · Beth Israel Deaconess Medical Center

B-cell directed therapies with or without a standard of care (SoC) are not regarded as first-line therapies for lupus nephritis. Following the case series of successful treatments of lupus nephritis with rituximab, the LUNAR study showed that rituximab+SoC improved immunologic parameters but not cli...

Register or Sign In to see full answer

In the treatment of lupus nephritis, which patients may benefit from the use of rituximab or other B-cell depleting agents during induction? | Mednet